Gleevec Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE43932 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5521184 NOVARTIS Pyrimidine derivatives and processes for the preparation thereof
Jan, 2015

(9 years ago)

US5521184

(Pediatric)

NOVARTIS Pyrimidine derivatives and processes for the preparation thereof
Jul, 2015

(9 years ago)

US7544799 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jan, 2019

(5 years ago)

USRE43932 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jan, 2019

(5 years ago)

US6894051 NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
May, 2019

(5 years ago)

USRE43932

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2019

(5 years ago)

US7544799

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Jul, 2019

(5 years ago)

US6894051

(Pediatric)

NOVARTIS Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
Nov, 2019

(4 years ago)

US6958335 NOVARTIS Treatment of gastrointestinal stromal tumors
Dec, 2021

(2 years ago)

US6958335

(Pediatric)

NOVARTIS Treatment of gastrointestinal stromal tumors
Jun, 2022

(2 years ago)



Gleevec is a drug owned by Novartis Pharmaceuticals Corp. It is used for treating tumors and gastrointestinal stromal tumors (GIST) in patients with CD117 positive unresectable or metastatic disease. Gleevec uses Imatinib Mesylate as an active ingredient. Gleevec was launched by Novartis in 2001. It is is available in the following dosage forms - capsule form for oral use, tablet form for oral use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 19, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using IMATINIB MESYLATE ingredient

Market Authorisation Date: 10 May, 2001

Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)

Dosage: CAPSULE; TABLET

How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage

GLEEVEC family patents

Family Patents